Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

COMPLETED

Identifier: CI-TRIAL-00073752
Entity page: /trial/NCT01527149 ↗
Edges: 10

Neighbours: 1 cancers7 drugs
Drawn: 8 of 8 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma condition of …CONDITION_OFderived3 of 3
← condition of	Mantle Cell Lymphoma registry condition “Stage III Mantle Cell Lymphoma” mapped CURATED_BROADER	—	—	Mantle Cell Lymphoma	1	Observed	clinicaltrials	graph →
← condition of	Mantle Cell Lymphoma registry condition “Stage I Mantle Cell Lymphoma” mapped CURATED_BROADER

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma intervention of …INTERVENTION_OFderived7 of 7
← intervention of	Cyclophosphamidesmall molecule registry intervention “Cyclophosphamide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cytarabinesmall molecule registry intervention “Cytarabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Dexamethasonesmall molecule registry intervention “Dexamethasone” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Doxorubicinsmall molecule registry intervention “Doxorubicin Hydrochloride” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Methotrexatesmall molecule registry intervention “Methotrexate” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Ofatumumabmonoclonal antibody registry intervention “Ofatumumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Vincristinesmall molecule registry intervention “Vincristine Sulfate” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma intervention of …INTERVENTION_OFderived7 of 7

← intervention of

Cyclophosphamidesmall molecule

registry intervention “Cyclophosphamide” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Cytarabinesmall molecule

registry intervention “Cytarabine” (DRUG) mapped ALIAS

—